Your browser doesn't support javascript.
loading
The potential of fecal microbiota transplantation in oncology.
Lythgoe, Mark P; Ghani, Rohma; Mullish, Benjamin H; Marchesi, Julian R; Krell, Jonathan.
Afiliação
  • Lythgoe MP; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK. Electronic address: M.Lythgoe@imperial.ac.uk.
  • Ghani R; Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, St Mary's Hospital Campus, Imperial College London, London, UK.
  • Mullish BH; Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, St Mary's Hospital Campus, Imperial College London, London, UK.
  • Marchesi JR; Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, St Mary's Hospital Campus, Imperial College London, London, UK.
  • Krell J; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK.
Trends Microbiol ; 30(1): 10-12, 2022 01.
Article em En | MEDLINE | ID: mdl-34711461
ABSTRACT
Immune checkpoint inhibitors (ICPIs) are efficacious treatments for several cancers. However, most patients fail to demonstrate durable complete responses. The gut microbiome composition influences the ICPI response. Two recent proof-of-concept studies have demonstrated the utility of fecal microbiota transplantation to transform ICPI responsiveness in refractory patients, providing intriguing evidence for the future of microbiota modulation within oncology.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Microbiota / Microbioma Gastrointestinal / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Microbiota / Microbioma Gastrointestinal / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article